Intranasal Oxytocin Explored as Augmentation for PTSD Therapy

Posttraumatic stress disorder (PTSD) is a chronic, debilitating anxiety disorder that can develop after traumatic events. Prolonged Exposure (PE) is a highly effective cognitive-behavioral psychotherapy for PTSD. The neuropeptide oxytocin shows promise as a pharmacotherapeutic agent with significant anxiolytic effects (anxiety-reducing properties). Despite a strong theoretical basis, no studies have previously investigated combining PE with intranasal oxytocin to enhance PTSD treatment outcomes.

The Phase 2 study successfully completed its enrollment of 17 participants, investigating the impact of 40 IU intranasal oxytocin on PTSD symptoms when combined with Prolonged Exposure (PE) therapy. While specific quantitative outcomes regarding symptom reduction are not detailed in this summary, the study aimed to determine if oxytocin augmentation would lead to a significant reduction in PTSD symptom severity compared to placebo. The design was randomized and quadruple-blind, ensuring robust methodology for assessing potential therapeutic benefits. The primary objective was to examine changes in PTSD symptoms following PE treatment augmented with either 40 IU intranasal oxytocin or a saline placebo, addressing a critical gap in the literature. The study's completion indicates that data was collected to evaluate the hypothesis that oxytocin could enhance the efficacy of PE for PTSD.